biocon wait for the dip opportunity to invest

Biocon is currently trading around ₹377–378, after closing at ₹382.15 on 25 September. The stock has corrected from its 52-week high of ₹447.15, while the 52-week low is around ₹337.05. Technical View Current structure: The stock is in a short-term corrective phase after failing to sustain the higher levels around ₹395–400. Important levels: Immediate Resistance: ₹390–395 Major Resistance: ₹405–415 Strong Resistance: ₹430–447 Immediate Support: ₹375–370 Major Support: ₹355–360 Strong Support: ₹337–340 A sustained move above ₹395–400 could improve the short-term technical structure, while a decisive breakdown below ₹370 would indicate further weakness and bring the lower support zones into focus. Recent trading data shows Biocon moving from ₹395.45 on 23 September to ₹387.20 on 24 September and ₹382.15 on 25 September, confirming the recent loss of momentum. Fundamental Snapshot Biocon reported Q1 FY27 operating revenue of ₹4,336 crore, up 10% YoY, while EBITDA was ₹902 crore. Biopharma revenue grew 17% YoY, with biosimilars up 16% and generics up 21%. Net profit was approximately ₹137 crore, up more than 50% YoY, although sequentially profit declined from the previous quarter. Above ₹400: the chart structure can turn stronger, with ₹415 and then higher resistance zones becoming relevant. Below ₹370: caution increases, with ₹355–360 and subsequently ₹337–340 becoming important support areas. For an investor, the fundamental growth in Biopharma and biosimilars is an important factor, while the technical setup currently suggests waiting for confirmation rather than assuming a trend reversal. Important: This is an educational/analytical view, not a recommendation to buy or sell. Actual investment decisions should consider your risk profile, holding period and the latest exchange disclosures.